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Green tea extracts containing 
epigallocatechin‑3‑gallate 
modulate facial development 
in Down syndrome
John M. Starbuck1,2, Sergi Llambrich3, Rubèn Gonzàlez4, Julia Albaigès5,6,7, 
Anna Sarlé4, Jens Wouters3, Alejandro González8, Xavier Sevillano8, James Sharpe5,9,10, 
Rafael De La Torre11,12, Mara Dierssen5,6,7,13, Greetje Vande Velde3,13 & 
Neus Martínez‑Abadías4,5,10,13*
Trisomy of human chromosome 21 (Down syndrome, DS) alters development of multiple organ 
systems, including the face and underlying skeleton. Besides causing stigmata, these facial 
dysmorphologies can impair vital functions such as hearing, breathing, mastication, and health. To 
investigate the therapeutic potential of green tea extracts containing epigallocatechin‑3‑gallate 
(GTE‑EGCG) for alleviating facial dysmorphologies associated with DS, we performed an experimental 
study with continued pre‑ and postnatal treatment with two doses of GTE‑EGCG supplementation 
in a mouse model of DS, and an observational study of children with DS whose parents administered 
EGCG as a green tea supplement. We evaluated the effect of high (100 mg/kg/day) or low doses 
(30 mg/kg/day) of GTE‑EGCG, administered from embryonic day 9 to post‑natal day 29, on the facial 
skeletal development in the Ts65Dn mouse model. In a cross‑sectional observational study, we 
assessed the facial shape in DS and evaluated the effects of self‑medication with green tea extracts 
in children from 0 to 18 years old. The main outcomes are 3D quantitative morphometric measures 
of the face, acquired either with micro‑computed tomography (animal study) or photogrammetry 
(human study). The lowest experimentally tested GTE‑EGCG dose improved the facial skeleton 
morphology in a mouse model of DS. In humans, GTE‑EGCG supplementation was associated with 
reduced facial dysmorphology in children with DS when treatment was administered during the first 
3 years of life. However, higher GTE‑EGCG dosing disrupted normal development and increased facial 
dysmorphology in both trisomic and euploid mice. We conclude that GTE‑EGCG modulates facial 
development with dose‑dependent effects. Considering the potentially detrimental effects observed 
in mice, the therapeutic relevance of controlled GTE‑EGCG administration towards reducing facial 
dysmorphology in young children with Down syndrome has yet to be confirmed by clinical studies.
Trisomy 21, an aneuploidy referred to as Down syndrome (OMIM 190685), is a complex genetic disorder and 
the most frequent genetic cause of intellectual disability, affecting one out of 700–1000 live-born individuals 
1. The overexpression of hundreds of triplicated chromosome 21 genes causes a dosage imbalance that alters 
signaling pathways regulating the development of multiple tissues and organs 1 such as the brain, heart, immune 
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system, gastrointestinal tract, and skeleton. Trisomy 21 is associated with characteristic facial features, including 
midfacial flatness, oblique palpebral fissures, mandibular hypoplasia, and facial asymmetry 2. Such dysmorphol-
ogy, together with muscular dysfunction, result in a higher prevalence of malocclusion 3, mouth breathing and 
obstructive sleep apnea, and potentially compromises quality of life.
The genetic complexity of trisomy 21, combined with large degrees of developmental and phenotypic variabil-
ity in individuals with Down syndrome, represents a serious challenge to any attempt to alleviate the alterations 
induced by this aneuploidy. Nevertheless, green tea extracts (GTE) enriched in catechins such as epigallocate-
chin-3-gallate (EGCG) have emerged as a promising therapeutic tool for individuals with Down syndrome 4–9. 
Although the effect of GTE-EGCG is not specific, and different catechins or combinations of catechins may 
have different effects on Down syndrome phenotypes 7, accumulating evidence suggests that the ability of GTE-
EGCG to inhibit the excess kinase activity 10 of the dual specificity tyrosine-phosphorylation-regulated kinase 
1A (DYRK1A) may play a prominent role 11.
The gene encoding for this kinase, DYRK1A, maps to the 21q22.2 region, whose duplication is associated 
with facial and cognitive phenotypes 12. DYRK1A is part of a complex genetic regulatory circuit at the crossroads 
of many important processes and developmental pathways, including development of the brain 13, face 14, skel-
eton 6,7, and heart 15. Thus, DYRK1A kinase inhibition by GTE-EGCG has the potential to influence multiple 
altered phenotypes associated with Down syndrome. Whether the effect of GTE-EGCG is through modulation 
of DYRK1A kinase activity or by acting on other genes or mechanisms is not completely characterized 16. How-
ever, it is broadly recognized that DYRK1A is a good therapeutic target for Down syndrome 9,17. Gene dosage 
imbalances in DYRK1A are associated with neural dysfunction, skeletal alterations, speech impairment, and/
or brain and craniofacial dysmorphology 18 (i.e. microcephaly, brachycephaly). These phenotypic changes arise 
either from DYRK1A deficiency, such as in MRD7 autism spectrum disorder 11 and in syndromes caused by 
DYRK1A microdeletions 19, or from DYRK1A excess combined with other triplicated chromosome 21 genes, 
such as in Down syndrome 20.
Besides Dyrk1A kinase activity, GTE-EGCG may inhibit several DYRK1A related pathways such as the 
NFAT (Nuclear factor of activated T-cells) signaling pathway and transcription factors DCAF7 21 and GLI1 22, 
which are overexpressed in Down syndrome and play a role as critical regulators of vertebrate development 
and organogenesis, including skeletal, muscular and cardiac development 15. Specific to facial morphogenesis, 
GTE-EGCG could alter the role of DYRK1A in a network of calcium signaling genes regulated by retinoic acid 
(RA)23. Inhibiting transcriptional activity of NFAT by phosphorylation, DYRK1A can inactivate the transcrip-
tion of genes that regulate neural crest cell migration and patterning of facial prominences during early orofacial 
development 23. Experimental research supports that Dyrk1a is expressed in the embryonic structures that give 
rise to the orofacial region and the brain 14,23,24, and contributes to regulate pre- and postanatal bone development 
25. Thus, DYRK1A may have a direct role in facial development regulating the development of facial primordia 
into the osseous structures of the adult face, as well as an indirect role by controlling the growth of the forebrain 
24, which acts as a mechanical substrate and a signaling center for early facial development 26. Through these 
complex signaling pathway interactions, DYRK1A may integrate craniofacial and brain development.
Overexpressed DYRK1A is also linked to cognitive impairment 26. Experimental mouse studies and clinical 
trials with adult individuals suggest that DYRK1A kinase inhibition by GTE-EGCG is involved in the improve-
ment of adaptive functionality and cognitive deficits associated with Down syndrome 5,8. Studies using partially 
trisomic Down syndrome mouse models or transgenic mice that overexpress Dyrk1a indicate that GTE-EGCG 
ameliorates some cognitive 26, skull 18 and skeletal alterations 6,7. However, GTE-EGCG supplementation out-
comes differ greatly depending on the treatment conditions (i.e. dosage, onset, duration of the treatment, as well 
as GTE composition, brand and administration method) 27. For example, a study in Ts65Dn mice found that 
1 month of 2–3 mg of EGCG per day can improve cognition in adult mice 5, while another study failed to find 
such improvements in Ts65Dn mice treated with ~ 10, ~ 20, or ~ 50 mg/kg/day of EGCG starting at P24 for 3- or 
7-weeks 27. Regarding skeletal development, EGCG administered to pregnant Ts65Dn dams (200 mg/kg/day on 
E7 and E8), permanently rescued cranial vault morphology in the offspring 18. Similarly, in 3 week old Ts65Dn 
mice, treatment with a low dose of EGCG (~ 9 mg/kg/day for 3 weeks beginning in early adulthood) improved 
femoral bone mineral density and trabecular microarchitecture 6. However, Ts65Dn mice treated with a higher 
dose ~ 50 mg/kg/day of EGCG for 7 weeks starting at P24 exhibited detrimental effects on femoral bone struc-
ture, such as reductions in cortical area, thickness, and structural strength 27. Consequently, an optimal effective 
GTE-EGCG treatment regime to improve cognitive development and morphogenesis in individuals with Down 
syndrome is still under debate 27.
To evaluate the therapeutic potential of GTE-EGCG upon facial development, we assessed the effects of two 
different doses of continued pre- and postnatal GTE-EGCG treatment on a mouse model of Down syndrome. 
We also analyzed, for the first time, facial morphology of children with Down syndrome that received different 
over-the-counter treatments based on GTE-EGCG supplementation.
Results
Dose‑dependent effects of GTE‑EGCG on facial shape in Down syndrome mouse model. We 
experimentally evaluated the effect of a green tea extract (GTE-EGCG; Mega Green Tea Extract, Life Exten-
sion, USA) on the facial skeletal development of a Ts65Dn (TS) mouse model. Ts(1716)65Dn mice carry a freely 
segregating marker chromosome that consists of a translocation of the telomeric region of Mmu16 onto the 
centromeric region on Mmu17, resulting in mice that are trisomic for orthologs of approximately half of the 
genes on Hsa21 28–30. This well-established genetic murine model of Down syndrome reproduces many anatomi-
cal abnormalities found in humans with trisomy 21, including neuroanatomical changes, impaired learning, 
memory and craniofacial phenotypes 31. We administered either high (100 mg/kg/day) or low doses (30 mg/
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kg/day) of GTE-EGCG in drinking water to TS and wild-type euploid (WT) mice from embryonic (E) day 9 to 
post-natal (P) day 29 (see Table 1 for sample composition). The GTE-EGCG solution was prepared freshly using 
the same batch of the Mega Green Tea Extract in all the experiments, with an estimated composition of 53.6% 
EGCG, 4.5% epicatechin (EC), 9% epicatechin gallate (ECG) and 12.5% epigallocatechin (EGC). Control litters 
received a control solution (see “Materials and methods” for further details).
We quantitatively compared the facial skeletal morphology of TS and WT mice, with and without treatment, 
using a quantitative shape analysis 32 based on the 3D coordinates of 12 anatomical facial landmarks registered 
on micro-computed tomographic (µCT) images of mouse craniofacial skeletons (Fig. S1A, Table S2). As sexual 
dimorphism was not a significant effect (Table 1 and Fig. S2), we performed our analyses on the pooled sample 
of male and female mice. To assess genotype and GTE-EGCG treatment effects on the murine facial skeleton, 
we performed a Principal Component Analysis (PCA). We explored facial shape variation among individuals by 
creating a morphospace based on the first two PCs, which together explained 49.6% of the total morphological 
variance among samples. In this scatterplot (Fig. 1), each point represented the facial shape of one individual and 
the experimental groups of mice were outlined using convex hulls. Close proximity between groups indicated 
similar facial phenotypes, while separation indicated dissimilarity. Our results showed genotype-dependent facial 
shape differences (Fig. 1). Untreated WT and TS mice clustered in separate morphospace groups with commen-
surate ranges of variation (Fig. 1). Compared to WT, TS mice exhibited midfacial hypoplasia and reduced facial 
dimensions, which corresponds to human trisomy 21 phenotypes (Fig. S3).
Table 1.  Mouse sample composition by experiment of low and high dose GTE-EGCG treatment. Sample 
sizes of treated and untreated wildtype (WT) and trisomic (TS) mice are provided, showing total number of 
mice, as well as number of mice separated by sex (Female/Male). Since permutation tests based on Procrustes 
distances between male and female mice showed that there are no significant facial shape differences due to 
sex (P = 0.2586) and male and female mice completely overlapped on the morphospace defined by a Principal 
Component Analysis (Fig. S2), we analysed the pooled data to increase the sample sizes and the robustness of 
the analyses.






High dose 7 (3/4) 8 (4/4)
Figure 1.  Principal Component Analyses of the global facial shape variation in Ts65Dn trisomic (TS) mouse 
models treated with high and low GTE-EGCG doses and euploid wild-type (WT) mice. Scatterplot of PC1 
and PC2 axes with the corresponding percentage of total morphological variation explained is displayed 
along each axis. Convex hulls and horizontal color bars represent the ranges of variation within each group of 
mice. To visualize facial shape changes associated with positive and negative extremes of PC1 and PC2, skull 
CT reconstructions of mice occupying these positions are displayed. Note that although the complete skull 
is displayed for anatomical reference, only landmarks located on the colored facial region have been used for 
the analysis. Colors correspond to mice groupings. The red colored skull to the far right representing a TS 
mouse treated with a high dose of GTE-EGCG exhibited poor bone mineral density as evidenced by the nearly 
transparent regions of cranial vault bones. See Fig. S3 to further visualize facial shape changes associated to PC1, 
which is the axis that explains most morphological variation and separates groups based on genotype. Mice skull 
reconstructions were obtained from NRecon and Amira, and landmarking was performed with Amira.
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The PCA analysis also revealed a GTE-EGCG dose-dependent treatment effect. Mice treated with high GTE-
EGCG doses exhibited atypically large facial morphological variation. Both WT and TS treated mice presented 
phenotypes that ranged from euploid to highly dysmorphic (Fig. 1), indicating that the effect of the high dose 
treatment was not homogeneous across groups and produced disparate effects. In the wild-type group, 43% of the 
WT treated mice fell close to the range of variation of non-treated WT mice and displayed typical euploid facial 
phenotypes, whereas 57% of the WT treated mice presented unusual facial dysmorphologies. In the trisomic 
group, 25% of the TS mice treated with high GTE-EGCG doses of the mice fell within the range of variation of 
WT non-treated mice, suggesting that the GTE-EGCG rescued the facial phenotype in those mice. However, the 
remaining 75% of the TS mice treated with the high dose occupied extreme morphospace positions associated 
with exacerbated facial dysmorphologies relative to non-treated TS mice (Fig. 1 and Fig. S3).
In contrast, low dose GTE-EGCG treatment produced more consistent effects across groups. Wild-type mice 
treated with low doses of GTE-EGCG presented euploid-like facial phenotypes within a range of variation that 
did not completely overlap with the range of variation of non-treated WT mice (Fig. 1). The GTE-EGCG treat-
ment similarly affected all WT mice, deviating their facial morphology towards slightly longer snouts. In trisomic 
mice treated with a low dose of GTE-EGCG, the treatment did not have any apparent effect in 40% of the TS 
mice, as these animals fell within the range of variation of non-treated trisomic mice. However, the remaining 
60% of TS mice exhibited facial phenotypes that overlapped with untreated WT mice (Fig. 1 and Fig. S3), sug-
gesting that the low dose GTE-EGCG treatment rescued their facial dysmorphology.
Our results showed that the effect of high GTE-EGCG doses on facial shape was highly variable, unpredict-
able, and potentially detrimental for both TS and WT mice, indicating a deleterious effect of the high dose 
GTE-EGCG treatment on facial morphology. On the contrary, low doses of GTE-EGCG normalized facial 
development and shape in most TS mice.
Finally, we carried out additional tests to evaluate the localized effects of GTE-EGCG treatment on facial 
shape. Euclidean Distance Matrix Analyses (EDMA) 33 revealed that 22.7% of facial measurements were signifi-
cantly different between untreated TS and WT mice (Fig. 2). This percentage decreased to 18.2% when TS mice 
were treated with a low-dose of GTE-EGCG, suggesting a slight facial morphology improvement. In high-dose 
GTE-EGCG treated TS mice, the percentage of facial differences increased to 50% on average, confirming that 
facial dysmorphology dramatically increased in most trisomic mice when treated with the high dose (Fig. 2).
We also estimated facial treatment scores (FTS) by combining the EDMA results with an additional iterative 
bootstrapping method. This is a novel approach to statistically quantify whether a treatment improves a disease-
altered morphology by reducing the morphological differences between treated and control groups. For each 
GTE-EGCG dose (high and low), FTSs were calculated as the relative difference in the percentage of significantly 
different facial traits between untreated and treated TS and WT mice (see “Materials and methods” for further 
details). We then implemented an iterative bootstrapping simulation approach to test FTS statistical significance. 
FTS values obtained from the experimental data were compared to randomly generated FTSs. For each high and 
Figure 2.  Localized Euclidean Distance Matrix Analysis facial shape pairwise contrasts for each mouse group of 
untreated wildtype (WT) and trisomic (TS) mice and low and high dose GTE-EGCG-treated mice. Results from 
the baseline contrast (TS vs WT) can be compared to results from high and low GTE-EGCG dose experiment to 
assess the effect of the treatment on Ts65Dn facial skeleton development. Black solid lines represent linear facial 
measurements that are significantly different in the two compared groups. Numbers indicate the percentage of 
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low GTE-EGCG dose, we used an iterative scaffolding approach to generate multiple random pseudo-subsamples 
of WT and TS individuals that progressively increased the number of treated individuals in the trisomic sample 
(from 0 to 7 in the high dose experiment; and from 0 to 4 in the low dose experiment). In each iteration, we 
recomputed the EDMA results and FTS scores and compared the distribution of randomly generated FTS values 
with the experimental value obtained from the complete sample of treated individuals (eight in the high dose 
experiment; and five in the low dose experiment) (Fig. S4). Although neither test reached statistical significance, 
histograms showed FTS trends for each experiment that were consistent with previous results. In the high GTE-
EGCG dose treatment comparison, the FTS decreased, indicating a worsening of facial shape. Conversely, in the 
low GTE-EGCG dose treatment comparison, the FTS increased, representing an improvement in facial shape. 
These results confirm a negative effect of high dose GTE-EGCG treatment, which on average increases facial 
differences between WT and TS mice, and a positive rescuing effect of low dose GTE-EGCG treatment on TS 
mouse model facial development.
Reduced facial dysmorphology in children with Down syndrome taking early GTE‑EGCG sup‑
plementation. We conducted a cross-sectional observational study to assess the facial shape in Down syn-
drome and to evaluate the effects of self-medication with green tea extracts in children from 0 to 18 years old 
(see Table 2 for cohort details and Table S1 for GTE-EGCG treatment details). The cohort included complete 
trisomy 21 cases who had or had not received GTE-EGCG supplementation, mosaic Down syndrome cases, and 
euploid children. In the GTE-EGCG treated group of children with Down syndrome, parents had administered 
their children commercially available green tea extracts containing EGCG obtained over-the-counter, for vari-
able periods and at different doses. Thus, the study participants did not follow a systematic GTE-EGCG usage 
pattern, as the dosage, onset, and treatment duration were not standardized, and no euploid treated control 
group was available. However, this observational study assesses for the first time whether GTE-EGCG can allevi-
ate facial dysmorphology in children with Down syndrome and reveal the need for a controlled clinical assay.
We assessed global facial shape differences between children with Down syndrome and euploid controls using 
a Procrustes shape analysis based on the 3D coordinates of 21 anatomical facial landmarks identified on their 
3D topographic images (Fig. S1B, Table S2). To determine whether the effects of GTE-EGCG supplementation 
were different depending on the developmental period, children were stratified into three developmental groups: 
babies/toddlers (0–3 years old), young children (4–12 years old), and adolescents (13–18 years of age) (Table 2). 
As sexual dimorphism was not a significant effect (Table 2), nor was the main source of facial morphological vari-
ation (Fig. S5), male and female data were pooled in all the analyses to increase sample sizes. We confirmed that 
the results from the pooled analyses were consistent with those resulting from analyses separated by sex (Fig. S6).
Results showed genotype-dependent differences in facial shape (Fig. 3 and Figs. S7 and S8). Euploid and 
Down syndrome groups were variable, as shown by the dispersion of the data in the PC scatterplots (Fig. 3), but 
their ranges of variation did not overlap. Overall, individuals with complete trisomy 21 presented flat and wider 
faces, oblique palpebral fissures, flat nasal bridges, wider noses, and thicker lips in comparison to euploid faces, 
while those with mosaic Down syndrome exhibited intermediate phenotypes (Figs. 3 and S7).
The position of GTE-EGCG-treated children with Down syndrome in the morphospace was different depend-
ing on the age (Fig. 3). When treatment started late in adolescence, treated and untreated adolescents with Down 
syndrome completely overlapped in the morphospace (Fig. 3a), suggesting that the GTE-EGCG treatment con-
ditions analyzed in this observational study did not show any relevant effect on facial shape during adolescence 
(Fig. 3a). At 4–12 years, GTE-EGCG treated children with Down syndrome tended to present intermediate 
phenotypes similar to mosaic cases, but larger samples are needed to confirm this result (Fig. S8). In the baby/
toddler group, most children with Down syndrome supplemented with GTE-EGCG presented less severe facial 
phenotype as compared to untreated cases (Fig. 3b). In particular, six out of seven (85.7%) GTE-EGCG-treated 
children with Down syndrome showed less facial dysmorphology than untreated children with Down syndrome 
Table 2.  Human cohort by age group. Total number of children as well as separated numbers by gender 
(Female/Male) are provided. As sexual dimorphism may affect facial shape, we assessed facial differences 
between males and females by computing the Procrustes distances among gender groups and a permutation 
test (10,000 rounds) in each age category. 0–3 years old group: Sexual dimorphism was not a significant 
factor (P(0–3) = 0.4965), and results did not differ when genders were analysed by separated (Figs. S3 and S4). 
4–12 years old group: sexual dimorphism was not significant (P(4–12) = 0.1470). However, as the sample size 
of the GTE-EGCG treated cases was limited, results are presented as “Supplementary Information” (Fig. S8). 
13–18 years old group: despite sexual dimorphism was significant (P(13–18) = 0.0138), we pooled male and 
female samples after checking that gender was not the main source of variation in the sample (Fig. S5) and 
that results separated by gender were consistent with the results from the pooled analyses (Fig. S6). In this 
group, we could not assess whether the treatment had a differential gender effect, as all the GTE-EGCG treated 
children were male.
DS Mosaic GTE-EGCG Euploid Total
0–3 years 20 (8/12) 3 (2/1) 7 (3/4) 57 (34/23) 87 (47/40)
4–12 years 27 (14/13) 1 (1/0) 2 (0/2) 100 (54/46) 130 (69/61)
13–18 years 16 (8/8) 0 4 (0/4) 50 (30/20) 70 (38/32)
Total 63 (30/33) 4 (3/1) 13 (3/10) 207 (118/89) 287 (154/133)
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from the same age range. From these, three of the treated children fell within the euploid range of facial shape 
variation, similar to the toddlers with mosaic Down syndrome (Fig. 3b), while the other three treated children 
fell in an intermediate morphospace position between the ranges of variation of euploid and Down syndrome 
toddlers (Fig. 3b). This suggests that the beneficial effects of GTE-EGCG on facial dysmorphology are variable 
but can be detected in most of the treated cases.
To pinpoint the exact facial region on which GTE-EGCG may have an ameliorative effect, we analyzed local 
facial shape differences using EDMA at the different stages (Fig. 4). In the adolescent group, 61.4% of linear meas-
ures significantly differed between genotypes (Fig. 4). GTE-EGCG-treated adolescent cases showed a relatively 
low reduction of dysmorphology, with 53.3% of linear distance measures being still significant after treatment. 
Indeed, only a minimal number of significant differences were detected (5.7%) between untreated and treated 
adolescents with Down syndrome, supporting that GTE-EGCG has little to no effect on facial dysmorphology 
when supplementation is initiated during adolescence. The FTS estimated in this age group was low and failed 
to reach statistical significance (P = 0.52) (Fig. 4).
In babies and toddlers, GTE-EGCG supplementation was associated with changes in various dimensions of 
the nose, philtrum, and midface (Fig. 4). While 57.6% of linear distances were significantly different between 
euploid and untreated children with Down syndrome, in GTE-EGCG supplemented children only 25.7% of lin-
ear distances remained significantly different from euploids (Fig. 4). The FTS was high (58%) in this age group, 
indicating a large ameliorative effect of GTE-EGCG on facial shape (Fig. 4). In the simulation analyses, only three 
randomly simulated datasets of children with Down syndrome provided a higher FTS than the observational 
data (Fig. 4), indicating that the GTE-EGCG treatment effect was statically significant (P = 0.008).
Further analyses confirmed that the GTE-EGCG treatment significantly affects facial shape at early stages but 
not later in development in this observational study. We computed the Procrustes distances between euploid and 
Figure 3.  Principal Component Analyses of the global facial shape variation in human children from different 
age groups. (a) Adolescents from 13 to 18 years old, and (b) Babies/toddlers to 3 years old. Scatterplots of 
PC1 and PC2 axes with the corresponding percentage of total morphological variance explained are displayed 
along each axis. Convex hulls represent the ranges of variation within each group of children. Anterior facial 
morphings associated with the extreme negative and positive values of PC1 are also shown. Orange solid 
lines represents facial phenotypes associated with Down syndrome, whereas blue solid line represents facial 
phenotype associated with euploid condition. Both shapes are compared to average facial shape, represented by 
a dashed grey line. Facial reconstructions were obtained from 3dMD and Agisoft PhotoScan, landmarks were 
recorded with PhotoModeler and morphings performed with Amira.
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Down syndrome treated and non-treated groups, and ran a permutation test for each age group. Results showed 
Figure 4.  Localized Euclidean Distance Matrix Analysis facial shape pairwise contrasts and iterative 
bootstrapping tests of facial changes due to treatment for each age group. Black solid lines represent linear 
facial measurements that are significantly different in the two compared groups. First row: children with Down 
syndrome (DS) versus euploid children (EU); second row: children with Down syndrome supplemented 
with GTE-EGCG (DS + GTE-EGCG) versus euploid children (EU), third row: GTE-EGCG supplemented 
(DS + GTE-EGCG) versus untreated children with Down syndrome (DS), last row: iterative bootstrapping tests 
based on facial treatment scores (FTS). FTS is computed by contrasting the number of significant differences 
in facial traits between (1) euploid children and untreated children with Down syndrome and (2) euploid 
children and GTE-EGCG treated children with Down syndrome. Histograms represent the simulation results 
for each random group separately (top rows) as well as grouped together (bottom row). Each group contains an 
increasing number of GTE-EGCG treated Down syndrome cases. The red line shows the FTS score obtained 
with the complete set of observed cases, including all GTE-EGCG treated Down syndrome cases, in each 
group. P-values are provided for each group, and statistically significant comparisons are marked with **. Facial 
reconstructions were obtained from 3dMD and Agisoft PhotoScan.
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that when the treatment was taken during adolescence, facial shape did not significantly differ of non-treated 
adolescents with Down syndrome (P = 0.5248). In contrast, when the GTE-EGCG treatment was taken early 
in development, during the first years of life, its positive effect on facial shape was significant (P = 0.0348). A 
MANOVA test confirmed that at early ages there are no sex differences regarding the effect of the treatment on 
facial shape (P = 0.409), which indicates that GTE-EGCG treatment potential is the same for males and females.
Discussion
Accumulating evidence is revealing that GTE-EGCG can modulate several aspects of phenotypes associated with 
trisomy 21 5–9,18. GTE-EGCG is known to modulate bone metabolism 34, formation 35, and resorption 36, poten-
tially by hindering osteoclastogenesis 36 and inducing osteoblast differentiation 37. Previous research has shown 
that high GTE-EGCG doses may suppress bone formation and exacerbate skeletal defects, whereas moderate 
GTE-EGCG doses may enhance bone formation and attenuate birth defects 35,38. Our study extends the evidence 
for the dosage dependency of the beneficial and detrimental effects of GTE-EGCG treatment to Down syndrome 
facial dysmorphology in Ts65Dn mice and provides the first observational evidence of supplementation effects 
in children with Down syndrome.
Our experimental results showed that GTE-EGCG treatment could reduce skeletal facial dysmorphology 
in trisomic Ts65Dn mice when administered from prenatal development until early adulthood at a low dose 
(30 mg/kg/day) (Figs. 1 and 2). However, the same treatment regime with a high GTE-EGCG dose (100 mg/
kg/day) could have detrimental effects, exacerbating facial dysmorphology in some treated mice (Figs. 1, 2 and 
Figs. S3, S4). For instance, we observed that after low dose treatment, facial phenotype was rescued in some 
trisomic mice but not in others, whereas after high dose treatment, mice presented facial shape changes that 
ranged from relatively normal facial morphology to severe facial dysmorphology (Fig. 1). Further experimental 
research is needed to understand the mechanisms by which the same GTE-EGCG treatment can alter facial devel-
opmental and induce completely different facial phenotypes in mice with identical genotypes. We hypothesize 
that beyond a certain dosage, GTE-EGCG treatment can induce such divergent facial phenotypes by hindering 
developmental stability 39.
Since facial soft-tissues are built upon the bony skull scaffold and individuals with Down syndrome experience 
impaired bone formation and growth 40 (e.g., shortened limbs, low bone mineral content and density, reduced 
bone strength and remodeling, osteopenia and osteoporosis that worsens with age), we hypothesize that GTE-
EGCG has a bone-remodeling effect on the face. Our results in the Ts65Dn mouse model support this assertion. 
Deficiencies in remodeling craniofacial bones 41 may explain the distinctive facial traits associated with trisomy 
21. Midfacial hypoplasia, as well as the altered shape and position of the maxilla, mandible, nasal, and orbital 
cavities present in Down syndrome 42, may result from increased bone resorption, reduced bone deposition, 
and/or lack of proper growth adjustments of these craniofacial bones, all of which have a higher predisposition 
to resorption 41.
Our observational study suggests that GTE-EGCG supplementation may have beneficial effects on facial shape 
of children with Down syndrome at early age (Figs. 3 and 4). Despite all the variability present in the human 
sample regarding treatment, gender and age (Table S1), we detected significant differences in children with Down 
syndrome administered with low doses of GTE-EGCG during the first three years of life as compared to children 
with Down syndrome that never received the treatment (Figs. 3 and 4). These facial differences included length, 
width, and depth dimensions of the midface local to the sagittal plane, specifically on the philtrum and nasal 
regions (Fig. 4). In older age groups, however, we found no evidence of a GTE-EGCG supplementation effect 
on facial shape (Fig. 4). Since the expected effect of variability in non-controlled studies is to weaken the signal 
of the treatment effect, the variability of treatments included in this observational study may have underscored 
the effects of GTE-EGCG in facial morphology in children with Down syndrome (Figs. 3 and 4, and Fig. S8), 
rather than artificially strengthening them. Our results are thus preliminary and require confirmation by clinical 
trials to provide any conclusive evidence about GTE-EGCG treatment.
Therefore, we hypothesize that the potential of GTE-EGCG treatment in facial bone remodeling is highest 
during early development in children (Figs. 3 and 4), while the skull and the face exhibit high growth velocities 
and rates of development 43, driven by rapid brain expansion and masticatory functional changes as offspring 
are weaned to solid foods. Afterwards, facial growth is much slower and bone remodeling activity is reduced. 
When the face has attained its final size and shape, usually around 13–16 years of age 43, there is little possibility 
to modify the facial shape since bone remodeling occurs only at low rates for homeostatic maintenance.
In conclusion, our experimental results, supported by the observational data, suggest that GTE-EGCG can 
modulate facial development to reduce dysmorphogenesis in Down syndrome. We report for the first time that, 
besides cognition and the skeletal system, green tea extracts may have gene-dosage dependent effects on facial 
shape. Further preclinical and clinical research is needed to explain the discordant and pleiotropic effects of 
GTE-EGCG under different treatment conditions and to identify an ideal therapeutic window and treatment 
regime to reduce facial dysmorphologies and associated comorbidities in Down syndrome. These investigations 
will pinpoint optimal dosage and timing for GTE-EGCG treatment, minimizing side effects and maximizing 
cognitive and biological growth benefits.
This research is critical because GTE-EGCG is commercially accessible over-the-counter and we found poten-
tially detrimental developmental effects on both trisomic and euploid conditions that warn against the general-
ized, non-prescribed intake of high GTE-EGCG doses as a health-promoting measure 44. To effectively translate 
this potential treatment into clinical practice, clinical trials with larger cohorts and controlled administration 
simultaneously assessing cognition, skeletal development, and growth on large pediatric samples are mandatory 
to identify the GTE-EGCG treatment that can reliably improve development in children with Down syndrome.
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Materials and methods
Experimental design. We performed two controlled experiments using the Ts65Dn mouse model to 
assess the effect of high and low GTE-EGCG treatment doses on the shape of the facial skeleton of adult mice. 
The study was carried out in compliance with the ARRIVE guidelines (Animal Research: Reporting of In Vivo 
Experiments).
Breeding conditions. Mice were housed at the animal facility of KU Leuven in standard individually ventilated 
cages (40 cm long × 25 cm wide × 20 cm high) under a 12 h light/dark schedule in controlled environmental 
conditions of humidity (50–70%) and temperature (22 ± 2 °C) with food and water supplied ad libitum. Water 
intake was monitored by cage.
Animals. For each experiment, we established a breeding colony composed of 4 WT males and 6 Ts65Dn 
females (Refs. 001875 and 001924, the Jackson Laboratory Bar Harbor, ME, USA). The Ts65Dn is a widely 
studied DS mouse model 45,46 that carries a segment with approx. 120 genes homologous to Hsa21 (starting 
upstream of Mrpl39 to the telomeric end of Mmu16), translocated to a small centromeric part of Mmu17 that is 
not syntenic to Hsa21 28,30. In total, we bred 55 Ts65Dn mice from eight litters (Table 1). Experimental protocols 
complied with all local, national and European regulations and were authorized by the Animal Ethics Commit-
tee of the KU Leuven (ECD approval number P004/2016) to optimize the minimization of animal sample size 
versus maximizing conclusive output in terms of statistical significance.
Treatment. We administered EGCG to 50% of randomly chosen pregnant dams to produce approximately the 
same number of GTE-EGCG-treated and non-treated mice. In one experiment, mice were treated with a high 
dose of GTE-EGCG (100 mg/kg/day), whereas in the other experiment mice received a lower dose (30 mg/
kg/day). Since EGCG crosses the placenta and reaches the embryo 4, treatment was administered prenatally 
at embryonic day 9 (E9). We chose this time point to optimize treatment efficiency, because this is when the 
face starts developing and Dyrk1A begins to be expressed in mouse embryos. GTE-EGCG treatment continued 
pre- and postnatally over the duration of the experiment, from E9 until adulthood at P29. During gestation 
and lactation, GTE-EGCG was delivered to dams dissolved in water at a concentration of 326 mg/L in the high 
dose experiment and 90 mg/L in the low dose experiment. After weaning at postnatal day 21 (P21) and until 
P29, GTE-EGCG dissolved in water at the same concentrations was made available to young mice that drank 
ad libitum. The GTE-EGCG solution was prepared freshly from a green tea extract (Mega Green Tea Extract, 
Life Extension, USA; EGCG content of 45% or 326.25 mg per capsule) every 3 days. We monitored water intake 
to control the amount of EGCG consumed by the dams and weaned mice. The dosage received was thus approxi-
mately 100 mg/kg/day in the high dose experiment, and 30 mg/kg/day in the low dose experiment for an adult 
mouse, considering that, on average, early adult mice weigh 20 g and drink 6 ml of water per day.
Morphometric facial study. Mice were genotyped by quantitative PCR from ear snips and were distributed 
in four groups according to their genotype and treatment: Euploid (WT), euploid treated with GTE-EGCG 
(WT + GTE-EGCG), trisomic Ts65Dn (TS) and trisomic Ts65Dn treated with GTE-EGCG (TS + GTE-EGCG). 
See Table 1 for details on sample composition. We acquired in vivo whole-body micro computed tomography 
(µCT) scans of mice at P29 using a high resolution (50 μm isotropic) dedicated fast low-dose in vivo µCT scan-
ner (SkyScan 1278, Bruker Micro-CT, Kontich, Belgium). Free-breathing mice were scanned under isoflurane 
anesthesia (~ 1–2% in oxygen), while physiological functions were constantly monitored and maintained (tem-
perature, breathing, visual inspection via camera). Scans were reconstructed using NRecon software (v1.6.10.4), 
whereas skull visualization and landmarking were performed by a single observer using Amira software (v6.3, 
Visualization Sciences Group, FEI). Measurement error was within the range of previous studies 47. To cap-
ture the shape differences between WT and TS mice and to assess whether EGCG treatment had an effect on 
facial development, we recorded the three-dimensional coordinates of a set of 12 facial anatomical landmarks 
(Fig. S1A and Table S2).
Patient cohort and recruitment. The human sample included 288 European and North American chil-
dren from 0 to 18 years old recruited for photographic sessions at schools, research centers, Down syndrome 
OPTIONS and family congresses between 2009 and 2017 (Table 2 and Table S1). All protocols were approved 
by ethics committees: Comité Ético de Investigación Clínica-Parc de Salut MAR, Nº 2012/4849/I; modificación 
24/07/2015; University Central Florida Institutional Review Board approval SBE-15-11524). To photograph the 
children and to obtain relevant clinical information, we obtained informed consent from their parents or legal 
guardians. All methods were carried out in accordance with relevant guidelines and regulations.
Facial image acquisition and anatomical landmark collection. Human faces were digitalized using non-invasive 
photogrammetry techniques. The facial images of each individual were acquired in an upright position with neu-
tral facial expression using either a 3dMD Face system (3dMD, Atlanta, GA) or self-built photographic rigs, as 
described elsewhere 42. Each system acquired 5–10 images simultaneously of an individual’s face and used pho-
togrammetry to merge separate two-dimensional (2D) images into a single three-dimensional (3D) model that 
accurately represents facial shape. The software used for obtaining the 3D reconstructions was 3dMD (3dMD, 
Atlanta, GA), PhotoModeler (v 1.1.1546, Eos Systems, Inc. Canada), and AgiSoft PhotoScan Standard (v 1.3.2). 
All data was collected with high precision and accuracy based on the same principles of stereo photogrammetry. 
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Scale differences from the different acquisition systems were accounted for in the subsequent analyses by trans-
forming pixel sizes to their corresponding mm measures.
We measured and recorded 3D coordinates of 21 facial landmarks from each individual’s 3D image follow-
ing published protocols 42 (Fig. S1B and Table S2). Measurement error was within the range of previous studies 
(0.26 mm along the x-dimension, 0.30 mm along the y-dimension, and 0.31 mm along the z-dimension) 2 and 
thus considered negligible. Following inspection of landmark coordinates for gross error, anatomical landmark 
coordinates were used to conduct morphometric analyses.
GTE‑EGCG supplementation. In this observational study, the cohort included cases of children with Down 
syndrome whose parents had administered them commercially available green tea extracts containing EGCG 
obtained over-the-counter. GTE-EGCG supplementation was variable for onset and duration of treatment, dos-
age and brand, as specified for each individual in Table S1.
Statistical analysis. We compared facial shape by integrating results from different morphometric meth-
ods 32,33, Procrustes and Euclidean Distance Matrix Analysis (EDMA), using MorphoJ 48 and Matlab (R2018a, 
MathWorks, Inc., Natick, MA, USA).
General Procrustes Analysis (GPA). We used this analysis 32 to assess global facial phenotype, analyzing facial 
shape as a whole 3D landmark configuration. Using this method, the 3D spatial relationship between landmarks 
was always preserved throughout the analysis. Following the standard General Procrustes Analysis, landmark 
facial shape configurations of all individuals were superimposed by shifting them to a common position, rotat-
ing, and scaling them to a standard size until a best fit of corresponding landmarks was achieved. Although the 
resulting Procrustes coordinates were scale-free, the shape data still contained a component of size-related shape 
variation due to allometry 49, which refers to organism shape change relative to body size changes that occur 
from growth during development. Since our human dataset included children of different ages, we removed the 
allometric effects by performing a multivariate regression of shape on age within each age group 49. The Pro-
crustes residuals from this regression were the input for further statistical analysis.
Principal Component Analysis (PCA). This multivariate technique was used to explore facial morphological 
variation 32 and to assess whether individuals grouped according to their genotype and/or treatment. PCA per-
forms an orthogonal decomposition of the data and transforms variance–covariance matrices into a smaller 
number of uncorrelated variables called Principal Components (PCs), which successively account for the largest 
amount of variation in the data. Each individual is then scored for every PC, and individuals are plotted using 
these scores along the morphospace defined by the principal axes as an ordination method to visualize patterns 
of shape variation associated with individual axes. The distribution of individuals and groups throughout the 
morphospace along different PC axes reveals similarities or differences, based on proximity to others, in facial 
shape and variation among groups. This ordination method allowed us to assess whether individuals with Down 
syndrome treated with GTE-EGCG presented an intermediate or rescued facial phenotype relative to untreated 
individuals with Down syndrome and euploid controls along the PC axes explaining the most variance across 
groups.
Euclidean Distance Matrix Analysis (EDMA). This is a robust morphometric method 33 for assessing local dif-
ferences between samples because it pinpoints exactly which linear measurements significantly differ between 
pairwise sample contrasts and compares patterns of significant differences across samples. In the human sam-
ple, two-tailed two-sample shape contrasts were conducted on all unique inter-landmark linear distances from 
each sample using a non-parametric bootstrap (10,000 resamples). A total of 210 unique facial measurements 
were calculated for each individual from Procrustes-based allometrically corrected shape coordinates. Linear 
distances were compared for each age group (0–3 years, 4–12 years, 13–18 years) of Down syndrome, Down 
syndrome treated with GTE-EGCG, and euploid individuals. Euclidean Distance Matrix Analysis statistically 
evaluated the number of significant local linear distances in each two-sample comparison based on confidence 
interval testing (α = 0.10). Significant differences were plotted upon facial figures to pinpoint specific local shape 
differences and reveal the unique morphological patterns of variation associated with each pairwise contrast.
Facial treatment score. We assessed whether facial change due to GTE-EGCG treatment was statistically sig-
nificant using a novel morphometric method that combines EDMA and iterative bootstrapping. First, we esti-
mated relative facial change from the EDMA results as the following percentage: [% significant distances (Down 
syndrome vs euploid) − % significant distances (Down syndrome treated with GTE-EGCG vs euploid)/% signifi-
cant distances (Down syndrome vs euploid)] × 100. To assess the statistical significance of the patterns revealed 
by EDMA, we ran iterative bootstrapping tests. We performed a subsampling approach in which we generated 
random pseudo-subsamples with increasing numbers of Down syndrome treated cases. For each age group, 
the whole sample was divided into groups of N individuals (where N is the number of GTE-EGCG-treated 
individuals with Down syndrome in the original sample) following a subsampling approach that randomly cre-
ated pseudo sub-samples containing a known number (namely M) of treated individuals, resulting in a series 
of staggered pseudo sub-samples containing from M = 0 to M = N treated individuals. We computed an EDMA 
and a facial treatment score (FTS) corresponding to each simulation and analyzed the FTS histogram of each 
random group. Finally, we computed an aggregated FTS histogram of all groups and compared the distribution 
of random FTSs with the observed FTS. The P-value of the comparison was computed as the ratio between the 
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number of simulations that provided a higher FTS than the observed FTS and the total number of simulations 
and was used to assess statistical significance (α = 0.05).
 Data availability
Raw phenotype data cannot be made available due to restrictions imposed by the ethics approval. Because of 
data size, mice scan data is available upon simple reasonable request to the corresponding author. Anonymized 
landmark data and Matlab code for computing Facial treatment score (FTS) is available at https ://githu b.com/
xavie rsevi llano /FIS_Analy sis_3D.
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